1. "Meeting abstract"
Formats
  1. Meeting Abstract (31714)
Groups
  1. Department of Medicine (14836)
  2. Solid Tumor Oncology Division (8682)
  3. GSK Faculty (6821)
  4. Hematologic Malignancies, Division of (5910)
  5. Center for Hematologic Malignancies (5803)
  6. Survivorship Research (4930)

More Groups

People
  1. Marc Ladanyi (623)
  2. Sergio Giralt (602)
  3. Victor Reuter (550)
  4. Robert Motzer (540)
  5. Miguel-Angel Perales (460)
  6. Howard Scher (456)

More People

Years
  1. 2024 (128)
  2. 2023 (1922)
  3. 2022 (2196)
  4. 2021 (1731)
  5. 2020 (1901)
  6. 2019 (2088)

More Years

Publications
  1. Journal of Clinical Oncology (5703)
  2. Blood (3812)
  3. Cancer Research (1821)
  4. Laboratory Investigation (1666)
  5. International Journal of Radiation Oncology, Biology, Physics (1521)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (5703)
  2. Elsevier Inc. (4343)
  3. American Society of Hematology (3812)
  4. American Association for Cancer Research (3044)
  5. Nature Publishing Group (1942)
  6. Oxford University Press (1893)

More Publishers

Results (31714)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Characterization of onset and resolution of adverse events in patients treated with naxitamab in trial 201
    Meeting Abstract

    Mora, J.; Chan, G. C. F.; Morgenstern, D.; Amoroso, L.; Nysom, K.; Faber, J.; Wingerter, A.; Bear, M.; Simon, A. R. S.; Kushner, B.; more...
    Pediatric Blood and Cancer (2023)

    Fulltext@MSK | Save
  • Results of the phase 2 cohort of lenvatinib (LEN) plus everolimus (EVE) in recurrent/refractory childhood solid tumors, performed in collaboration with the Children's Oncology Group
    Meeting Abstract

    Dela Cruz, F.; Fox, E.; Dubois, S.; Friedman, G.; Croop, J.; Kim, A.; Morgenstern, D.; Balis, F.; Macy, M.; Pressey, J.; more...
    Pediatric Blood and Cancer (2023)

    Fulltext@MSK | Save
  • Female breast cancer risk after anthracyclines for childhood cancer: An international pooled analysis
    Meeting Abstract

    Wang, Y.; Ronckers, C.; Van Leeuwen, F.; Moskowitz, C.; Leisenring, W.; Armstrong, G.; De Vathaire, F.; Hudson, M.; Kuehni, C.; Arnold, M.; more...
    Pediatric Blood and Cancer (2023)

    Fulltext@MSK | Save
  • POE14-01: A phase I study of carfilzomib in combination with cyclophosphamide and etoposide for children, adolescents and young adults with relapsed/refractory leukemias or solid tumors
    Meeting Abstract

    Boklan, J.; Narendran, A.; Bielamowicz, K.; Trippett, T.; Brown, V.; Dubois, S.; Eshun, F.; Gelfond, J.; Zomet, A.; Lacayo, N.; more...
    Pediatric Blood and Cancer (2023)

    Fulltext@MSK | Save
  • A comparison of neurocognitive outcomes after radiation therapy in pediatric ependymoma with or without maintenance chemotherapy: Findings from Children's Oncology Group clinical trial ACNS0831
    Meeting Abstract

    Kunin-Batson, A.; Lensing, S.; Smith, A.; Onar-Thomas, A.; Embry, L.; Ramjan, S.; Sands, S.
    Pediatric Blood and Cancer (2023)

    Fulltext@MSK | Save
  • Inhibition of ATM kinase by the CNS-penetrant AZD1390 enhanced radiotherapy in neuroblastoma and rhabdomyosarcoma preclinical models
    Meeting Abstract

    Burrow, T.; Graham, K.; Koneru, B.; Farooqi, A.; Houghton, P.; Dela Cruz, F.; Kalapurakal, J.; Reynolds, C. P.
    Pediatric Blood and Cancer (2023)

    Fulltext@MSK | Save
  • Sequential genomic analysis using a multisample/multiplatform approach to better define rhabdomyosarcoma progression and relapse
    Meeting Abstract

    De Traux De Wardin, H.; Dermawan, J.; Delattre, O.; Pierron, G.; Antonescu, C.
    Pediatric Blood and Cancer (2023)

    Fulltext@MSK | Save
  • Clinical and Wilms tumor characteristics of patients with heterozygous germline Dis3l2 variants
    Meeting Abstract

    Van Peer, S.; Treger, T.; Wegert, J.; Le Gall, J.; Jakkula, E.; Kamihara, J.; Mullen, E.; Graf, N.; Behjati, S.; Al-Saadi, R.; more...
    Pediatric Blood and Cancer (2023)

    Fulltext@MSK | Save
  • Naxitamab efficacy and safety in patients treated with and without steroid premedication
    Meeting Abstract

    Mora, J.; Chan, G. C. F.; Morgenstern, D.; Nysom, K.; Faber, J.; Wingerter, A.; Bear, M.; San Simon, A. R.; Kushner, B.; Tornoe, K.; more...
    Pediatric Blood and Cancer (2023)

    Fulltext@MSK | Save
  • Efficacy of naxitmab in refractory high-risk neuroblastoma
    Meeting Abstract

    Mora, J.; Chan, G. C. F.; Morgenstern, D.; Amoroso, L.; Nysom, K.; Faber, J.; Wingerter, A.; Bear, M.; San Simon, A. R.; Kushner, B.; more...
    Pediatric Blood and Cancer (2023)

    Fulltext@MSK | Save